BRCA1 and ovarian carcinoma: Since currently available PARG inhibitors are not satisfying so far, questioned either for their specificity or for their cell permeability [22], we evaluated the impact of PARG depletion by siRNA on cell survival of several breast and ovarian cancer cell lines either proficient or deficient in BRCA1.